Combination Treatment for Glioblastoma Cells with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Oncolytic Adenovirus Delta-24

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exhibits cancer-selective killing activity representing a promising anticancer therapeutic strategy. Adenovirus Delta-24 is another interested anticancer agent selectively killing cells with a defective p16/Rb/E2F pathway. However, many types of cancer, including gliomas, could develop resistance to Delta-24 or TRAIL-induced apoptosis. In this study, we investigated whether TRAIL, in combination with adenovirus Delta-24, could result in an enhanced antiglioma effect in vitro in a panel of glioblastoma cell lines (U87MG, U251MG, D54, and T98G). The treatment of glioblastoma cell lines with TRAIL and Delta-24 adenovirus in combination showed markedly enhanced effect, compared to each agent alone.

Keywords: :

• Adenovirus
• Apoptosis
• Caspase
• Delta-24
• Glioblastoma
• TRAIL

ACKNOWLEDGMENTS

This work was supported by a grant from Josef and Esther Gani Foundation (Ioannina, Greece). The authors would also like to thank Prof. E. Briasoulis and Dr. V. Kounnis for providing the xCELLigence system and technical assistance with these experiments.